P3 Health Partners Swings To Q2 Profit, Lifts 2026 Guidance; Stock Up

P3 Health Partners (PIII) reported Q2 2026 revenue of $386.4 million, up 9% from $355.8 million a year earlier, and swung to net income of $15.7 million versus a $43.7 million loss. Adjusted EBITDA was $54.4 million. The company raised FY2026 guidance to $80-$110 million adjusted EBITDA and $1.5-$1.6 billion revenue.

Original reporting
Published Aug 11, 2026, 8:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 8:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PIII
Bullish
medium confidence
Mentioned
$PIII
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$PIIIBullishHigh
01

Why it matters

The key tradable change is the raised FY2026 adjusted EBITDA outlook alongside a Q2 swing to net income and improved adjusted EBITDA, which can shift expectations for profitability trajectory through 2H 2026.

02

Market read

A same-day guidance raise with detailed profitability metrics is a direct catalyst for PIII positioning, especially for traders focused on healthcare services margin expansion.

03

What to watch

The article highlights a separation between reported medical margin and medical margin excluding favorable payer settlements and prior-year development, which could signal less repeatability than headline margins imply.

Relevance 9/10Novelty 9/10Timing: pre-market/overnight reaction to Q2 print and raised FY2026 guidance

Background

P3 Health Partners operates physician-led networks focused on value-based care and reports results using medical margin, PMPM metrics, and at-risk membership.

Company-level read

Ticker impact

$PIIIBullishMedium confidence
Context

P3 Health Partners reported Q2 2026 results and raised FY2026 adjusted EBITDA guidance to $80-$110 million from an FY2025 loss.

Expected impact

Bullish bias for the next several sessions, with follow-through dependent on whether investors focus on margin expansion versus membership contraction.

Evidence & confidence

The article provides concrete Q2 profitability metrics (net income swing, adjusted EBITDA improvement) plus a specific FY2026 guidance increase, which typically drives re-rating. However, it also notes at-risk membership fell ~10% YoY, which can temper the magnitude of the positive reaction.

Market effects

Value-based care and population management peers may see read-across on margin durability and contract/network restructuring effectiveness.

Limited direct regional impact; company is Nevada-based but revenue is tied to payer/provider networks.

Low global relevance; primarily a US healthcare services read-through.

Counterpoint

Investors may discount the guidance raise if the profitability improvement is partly driven by favorable payer settlements or one-time items, and if membership rationalization continues to pressure scale.

Key entities

  • P3 Health Partners Inc.

    Reported Q2 2026 revenue growth, swung to net income, and raised FY2026 guidance for adjusted EBITDA, revenue, and medical margin.

  • Dr. Aric Coffman

    CEO cited structural improvements across contracts, networks, and operations as the basis for the guidance raise.

Related articles

$PIIIMed

P3 Health (PIII) Q3 2026 Earnings Call Transcript

P3 Health (PIII) reported Q3 2026 Adjusted EBITDA of $21M, raising full-year guidance to $90M-$100M. CEO Aric Coffman highlighted medical cost management, quality improvements, and growth strategies. The company is expanding in existing markets and entering new ones, like Nebraska, with a capital-efficient approach.

$PIIIMed

P3 Health Partners Announces Third Quarter 2026 Results

P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 P3 Health Partners Announces Third Quarter 2026 Results Adjusted EBITDA of $21 Million for the Third Quarter and $101 Million Year-to-Date Raises Full-Year 2026 Adjusted EBITDA Guidance Midpoint Management to Host Conference Call and Webcast November 9, 2026 at 4:30

$PIIIMedAI 9/10

P3 Health Partners (PIII) Q2 2026 Earnings Call Transcript

P3 Health Partners (PIII) reported Q2 2026 adjusted EBITDA of $54.4 million versus a prior-year loss, on total revenue of $386.4 million (+9% YoY). At-risk membership fell 10% to 105,000. Net income was $15.7 million. The company raised full-year 2026 guidance to adjusted EBITDA of $80 million to $110 million and revenue of $1.5 billion to $1.6 billion.